Literature DB >> 2175579

Interleukin-1 induces collagenase production by recessive dystrophic epidermolysis bullosa fibroblasts.

K Nomura1, T Imaizumi, H Mikami, K Tamai, M Takahashi, I Hashimoto.   

Abstract

We examined the direct effect of interleukin-1 (IL-1) on the collagenase production by epidermolysis bullosa (EB) fibroblasts. Addition of IL-1 at concentrations of 2.5 x 10(-4) units/ml or below in the culture media greatly enhanced collagenase production by two cell lines of recessive dystrophic EB (RDEB) fibroblasts. They produced 4.82 +/- 0.04 to 5.93 +/- 0.39 units/ml of enzyme, as compared to 0.02 +/- 0.07 units/ml in the absence of IL-1. In contrast, collagenase production by two cell lines of dominant dystrophic EB (DDEB) and normal fibroblasts was not, or only slightly, increased up to 0.69 +/- 0.28 units/ml. IL-1 concentrations of 2.5 x 10(-3) units/ml or higher failed to induce collagenase production by all fibroblasts. 3H-thymidine uptake increased by about 110-376% of control after IL-1 treatment. In addition, these data were obtained using fibroblasts of the 13-15 passages, suggesting that the property might be determined genetically. Although RDEB seems to be a wide heterogeneous group, the present data strongly suggest that the property may be specific to and characteristic of some types of RDEB cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2175579     DOI: 10.1007/BF00372088

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  18 in total

1.  Response of epidermolysis bullosa fibroblasts to factors derived from macrophages and polymorphonuclear leukocytes in terms of collagenase production.

Authors:  K Nomura; T Imaizumi; D Sawamura; I Hashimoto; Y Katabira
Journal:  J Invest Dermatol       Date:  1988-02       Impact factor: 8.551

2.  A rapid assay method of collagenase activity using 14C-labeled soluble collagen as substrate.

Authors:  K Terato; Y Nagai; K Kawanishi; S Yamamoto
Journal:  Biochim Biophys Acta       Date:  1976-10-11

3.  Anchoring fibrils and type VII collagen are absent from skin in severe recessive dystrophic epidermolysis bullosa.

Authors:  L Bruckner-Tuderman; Y Mitsuhashi; U W Schnyder; P Bruckner
Journal:  J Invest Dermatol       Date:  1989-07       Impact factor: 8.551

4.  Macrophage-fibroblast interactions in collagenase production and cartilage degradation.

Authors:  G Huybrechts-Godin; P Hauser; G Vaes
Journal:  Biochem J       Date:  1979-12-15       Impact factor: 3.857

5.  Therapeutic efficacy of phenytoin in recessive dystrophic epidermolysis. A comparison of short- and long-term treatment.

Authors:  T W Cooper; E A Bauer
Journal:  Arch Dermatol       Date:  1984-04

Review 6.  Interleukin-1.

Authors:  C A Dinarello
Journal:  Rev Infect Dis       Date:  1984 Jan-Feb

7.  Human skin fibroblast collagenase inhibitor. Purification and biochemical characterization.

Authors:  G P Stricklin; H G Welgus
Journal:  J Biol Chem       Date:  1983-10-25       Impact factor: 5.157

8.  Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1).

Authors:  S B Mizel; J M Dayer; S M Krane; S E Mergenhagen
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

9.  Recessive dystrophic epidermolysis bullosa. Evidence for increased collagenase as a genetic characteristic in cell culture.

Authors:  E A Bauer; A Z Eisen
Journal:  J Exp Med       Date:  1978-11-01       Impact factor: 14.307

10.  Interleukin 1 stimulation of collagenase production by cultured fibroblasts.

Authors:  A E Postlethwaite; L B Lachman; C L Mainardi; A H Kang
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

View more
  1 in total

1.  Expression of collagenase and stromelysin in skin fibroblasts from recessive dystrophic epidermolysis bullosa.

Authors:  T Sato; K Nomura; I Hashimoto
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.